Clinical Trial

Serranator POINT FORCE Registry

Study acronym: POINT FORCE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 7, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this registry is to collect observational data under local standard of care and evaluate safety and performance of the Serranator® in treatment of peripheral artery disease (PAD), or dysfunctional native or synthetic arteriovenous dialysis fistulae in a real-world scenario. The data and conclusions derived from this study will be used to provide clinical evidence for the clinical evaluation process.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-12; most recent amendment 2026-05-01.
Status change: Not Yet Recruiting → Recruiting 2025-02-11
Trial Details
NCT Number NCT06687590
Lead Sponsor Cagent Vascular LLC
Collaborators: Yale Cardiovascular Research Group, Julius Clinical
Conditions Peripheral Artery Disease (PAD), Dysfunctional AV Fistula, Dysfunctional AV Graft
Enrollment 500 participants
Start Date 2025-01-22
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-07